piperidines and Pyoderma-Gangrenosum

Topics: Alopecia Areata; Colitis, Ulcerative; Humans; Piperidines; Pyoderma Gangrenosum; Pyrimidines

Pyoderma gangrenosum (PG) is a difficult-to-manage ulcero-necrotizing dermatosis associated with inflammatory bowel disease (IBD). In this article, we report a refractory PG in a patient with severe ulcerative colitis (UC) that responded to tofacitinib 10 mg/12 h.

Topics: Colitis, Ulcerative; Humans; Inflammatory Bowel Diseases; Piperidines; Pyoderma Gangrenosum; Pyrimidines

Pyoderma gangrenosum (PG) is a rare, debilitating, inflammatory skin disease associated with a variety of systemic diseases. Because of its rarity, PG is treated with miscellaneous immunosuppressive agents as there is no US Food and Drug Administration-approved standardized treatment approach. We present four patients with PG treated with tofacitinib in the context of the six existing cases in the literature. Tofacitinib appeared to be beneficial in the small sample of patients (n = 10) who failed an average of four other systemic therapies. The majority of patients had classic PG located on the legs (80%, 8/10), while 20% of cases (2/10) were peristomal. The most common comorbidity was inflammatory bowel disease (78%, 7/9). There were no negative treatment results and 40% (4/10) of patients had complete healing of their ulcers, while the other 60% (6/10) had marked clinical improvement. From our observation, tofacitinib appears to be a promising steroid-sparing adjuvant treatment in patients with refractory PG who have failed on other systemic therapies.

Topics: Adult; Aged; Aged, 80 and over; Dermatologic Agents; Female; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Leg Dermatoses; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyoderma Gangrenosum; Pyrimidines; Surgical Stomas; Treatment Outcome

Topics: Adenine; Antineoplastic Agents; Drug Eruptions; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyoderma Gangrenosum; Pyrazoles; Pyrimidines

Pyoderma gangrenosum (PG) is a difficult-to-treat inflammatory skin condition that affects inflammatory bowel disease (IBD) patients. There is no standardized approach for PG treatment.

Topics: Adult; Female; Histocytochemistry; Humans; Immunohistochemistry; Immunologic Factors; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyoderma Gangrenosum; Pyrimidines; Pyrroles; Skin; Treatment Outcome; Young Adult

Topics: Humans; Piperidines; Pyoderma Gangrenosum; Pyrimidines; Pyrroles

Topics: Adolescent; Drug Therapy, Combination; Female; Gastrointestinal Agents; Humans; Infliximab; Piperidines; Protein Kinase Inhibitors; Pyoderma Gangrenosum; Pyrimidines; Pyrroles; Treatment Outcome

Topics: Adenine; Cyclosporine; Drug Therapy, Combination; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Prednisone; Pyoderma Gangrenosum; Pyrazoles; Pyrimidines